These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 15070703

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K, Tanaka T, Kurokawa M, Imai Y, Ogawa S, Mitani K, Yazaki Y, Hirai H.
    Blood; 1998 Mar 01; 91(5):1688-99. PubMed ID: 9473235
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemia-related PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation.
    Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y.
    Mol Cell Biol; 1998 Jul 01; 18(7):4252-61. PubMed ID: 9632809
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates.
    Adya N, Stacy T, Speck NA, Liu PP.
    Mol Cell Biol; 1998 Dec 01; 18(12):7432-43. PubMed ID: 9819429
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells.
    Wijmenga C, Gregory PE, Hajra A, Schröck E, Ried T, Eils R, Liu PP, Collins FS.
    Proc Natl Acad Sci U S A; 1996 Feb 20; 93(4):1630-5. PubMed ID: 8643682
    [Abstract] [Full Text] [Related]

  • 13. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta.
    Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, Ishii S, Ogata K.
    Cell; 2001 Mar 09; 104(5):755-67. PubMed ID: 11257229
    [Abstract] [Full Text] [Related]

  • 14. Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor.
    Yoshida N, Ogata T, Tanabe K, Li S, Nakazato M, Kohu K, Takafuta T, Shapiro S, Ohta Y, Satake M, Watanabe T.
    Mol Cell Biol; 2005 Feb 09; 25(3):1003-12. PubMed ID: 15657428
    [Abstract] [Full Text] [Related]

  • 15. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.
    Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, Rossier C, Antonarakis SE, Israels S, McNicol A, Weiss H, Horwitz M, Scott HS.
    Blood; 2002 Feb 15; 99(4):1364-72. PubMed ID: 11830488
    [Abstract] [Full Text] [Related]

  • 16. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
    Barseguian K, Lutterbach B, Hiebert SW, Nickerson J, Lian JB, Stein JL, van Wijnen AJ, Stein GS.
    Proc Natl Acad Sci U S A; 2002 Nov 26; 99(24):15434-9. PubMed ID: 12427969
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
    Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zörnig M, Ottmann OG, Grez M.
    Cancer Res; 2007 Mar 01; 67(5):2280-9. PubMed ID: 17332359
    [Abstract] [Full Text] [Related]

  • 20. HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
    Richter LE, Wang Y, Becker ME, Coburn RA, Williams JT, Amador C, Hyde RK.
    Mol Cancer Res; 2019 Jun 01; 17(6):1241-1252. PubMed ID: 30814129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.